Clinical Trials
253
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (203 trials with phase data)• Click on a phase to view related trials
A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma
- Conditions
- Intrahepatic Cholangiocarcinoma (Icc)Adjuvant ChemoradiotherapyNarrow MarginLymph Node Involvement
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Target Recruit Count
- 66
- Registration Number
- NCT07063888
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Target Recruit Count
- 40
- Registration Number
- NCT07057102
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
- Conditions
- Medullary Thyroid Cancer (MTC)
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Target Recruit Count
- 40
- Registration Number
- NCT07048964
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
- Conditions
- Solid TumorsHematological TumorChildrenAdolescentChemotherapy Induced Thrombocytopenia
- Interventions
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Target Recruit Count
- 50
- Registration Number
- NCT07043894
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- Radiation: Long-course concurrent chemoradiotherapyRadiation: Short-course radiotherapyCombination Product: CAPOX
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Target Recruit Count
- 228
- Registration Number
- NCT07040098
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
🇨🇳National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Shenzhen, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 51
- Next